# OnCo record hla-a-02-01 (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/hla-a-02-01/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "hla-a-02-01" ;
  schema:name "HLA-A*02:01 (HLA typing for TCR therapies)"@en ;
  schema:alternateName "HLA-A*02:01"@en, "HLA-A2"@en, "HLA-A*02:01-positive"@en, "HLA-A0201"@en, "HLA typing"@en, "HLA-A*02"@en ;
  schema:description "HLA-A*02:01 is the commonest tissue-type molecule in people of European descent and the one the first T-cell receptor therapies were built for. Tebentafusp and afamitresgene autoleucel work only in patients who carry it, so a blood HLA test comes before the tumour test."@en ;
  schema:url <https://onco.cc/biomarkers/hla-a-02-01/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a49f57-d2fc-4ffe-9eb1-fe0460c6b067>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab24631f-3364-46e1-8074-7244863bcbab> ;
  onco:tag "biomarker", "hla" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-cps/> ;
  onco:cancers <https://onco.cc/cancers/uveal-melanoma/>, <https://onco.cc/cancers/synovial-sarcoma/>, <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/drugs/afamitresgene-autoleucel/> ;
  onco:terms <https://onco.cc/terms/hla-a02-restriction/>, <https://onco.cc/terms/uveal-melanoma-prognostic-markers/> .